CMMB Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	23 537.00
Gjennomsnittsvolum	220 504
Markedsverdi	9.09M
EPS	$0 ( 2024-03-07 )
Neste inntjeningsdato	( $-0.200 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.310
ATR14	$0.0120 (1.89%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-14	Darvish Nissim	Buy	20 572	Option to Purchase American Depositary Shares
2021-04-19	Darvish Nissim	Buy	11 884	Option to Purchase American Depositary Shares
2016-10-28	Darvish Nissim	Buy	10 123	Option to Purchase American Depositary Shares
2023-03-16	Darvish Nissim	Buy	6 857	Option to Purchase American Depositary Shares
2022-03-07	Darvish Nissim	Buy	6 820	Option to Purchase American Depositary Shares

INSIDER POWER
-57.70
Last 88 transactions
Buy: 2 375 207 \| Sell: 4 584 307

Anchiano Therapeutics Ltd Korrelasjon

10 Mest positive korrelasjoner
SNGX	0.895
LAWS	0.894
NAKD	0.892
DTSS	0.891
CFMS	0.886
IMV	0.885
TNGX	0.883
PIXY	0.883
DBGI	0.875
MRNA	0.875

10 Mest negative korrelasjoner
SJ	-0.906
MLTX	-0.893
ACVA	-0.893
PEGA	-0.888
KIN	-0.886
TA	-0.885
NCAC	-0.883
CONX	-0.879
NEO	-0.877
MYNA	-0.876

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Anchiano Therapeutics Ltd Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-66 827.00 (0.00 %)
EPS:	$-2.06

FY	2023
Omsetning:	$0
Bruttogevinst:	$-66 827.00 (0.00 %)
EPS:	$-2.06

FY	2022
Omsetning:	$0
Bruttogevinst:	$-57 773.00 (0.00 %)
EPS:	$-2.43

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.200

Financial Reports:

No articles found.

Anchiano Therapeutics Ltd

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.